Hepatitis C - Sofosbuvir-regimen outperformed other therapies in reducing liver complications

New @ Healio

Sofosbuvir-regimen outperformed other therapies in reducing liver complications in HCV patients
May 27, 2014
CHICAGO — Chronic hepatitis C virus-infected patients treated with a sofosbuvir-based regimen showed a reduced number of liver disease complications, compared with patients receiving other treatments, according to research presented at Digestive Disease Week 2014.

Sammy Saab, MD, MPH, AGAF, of UCLA Medical Center, and colleagues used a decision-analytic Markov model to compare health outcomes among chronic hepatitis C virus (HCV) patients with genotypes 1 to 4 who received a combination of sofosbuvir (SOF; Sovaldi, Gilead Sciences) and other therapies with HCV patients who did not. Outcome measures included complications resulting in mortality, liver transplantation, compensated cirrhosis, decompensated cirrhosis and hepatocellular carcinoma.
Full Story

Nosocomial infections among cirrhotic patients increased, associated with mortality 

Singal AK. Aliment Pharmacol Ther. 2014;doi:10.1111/apt.12797.

The rates of hospitalized patients with cirrhosis who were diagnosed with bacterial infections have increased and contributed to overall mortality, according to data from a new study.

 Full Story

Area poverty rate linked to incidence of certain cancers
May 27, 2014

Incidence of certain cancers in specific neighborhoods varied considerably based on the area’s poverty level, according to study results.

Researchers determined males were more sensitive to the associations between cancer rates and poverty, particularly for liver and interhepatic bile duct, lung and bronchus, anus, colon and rectum, oral cavity, pharynx and miscellaneous cancers.

Full Story